Please login to the form below

Not currently logged in
Email:
Password:

Kymab appoints its first chief medical officer

Dr Sonia Quaratino joins the firm from Novartis

Sonia QuaratinoKymab has appointed Dr Sonia Quaratino as its chief medical officer - a newly created role that will see her manage clinical development of the group’s expanding therapeutic antibody portfolio.

She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.

Dr Quaratino said: “Kymab’s emerging human antibody pipeline provides great potential to improve patient treatment options in our four main therapeutics areas of focus."

She previous served Novartis as its global clinical programme leader, transitional clinical oncology, with responsibility for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology.

Prior to her time at Novartis, Quaratino worked for Merck Serono, where she was responsible for the clinical development of various immunomodulators.

Dr David Chiswell, CEO of Kymab, said: “I am delighted to welcome Sonia to Kymab. With her track demonstrated track record in clinical development and medical affairs, Sonia is a superb addition to Kymab’s management team as we prepare for our first clinical trials.

“Sonia’s deep understanding of the global environment in clinical research compliment those of Dr Arndt Schottelius, our new executive VP of R&D. These two key appointments add high calibre of depth and provide further validation to our burgeoning and advancing R&D pipeline.”

10th May 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics